The contract requires a vendor to supply blood collection tubes, reagents, and controls for QuantiFERON-TB Gold Plus testing performed on the DiaSorin LIAISON XL instrument. Testing will be conducted at the Pathology & Laboratory Medicine Service (CSI section) of the VANTHCS in Dallas, TX. The base performance period runs from December 1, 2026, through November 30, 2027, with four additional option years extending through November 30, 2031. The contractor must ensure all tests meet manufacturer specifications, correct any performance deviations, provide timely notifications of reagent or equipment changes, and cover costs for referral lab testing if the facility cannot perform tests due to product or instrument issues. The contractor requires no access to VA systems, no VA data may be transferred, and all records created during the contract must be returned to VANTHCS.

The contract is for supplies and reagents to perform QuantiFERON-TB Gold Plus testing on a DiaSorin LIAISON XL instrument. Testing will be performed at the Client Services and Immunopathology (CSI) section of Pathology & Laboratory Medicine Service at VANTHCS, 4500 S. Lancaster Rd, Dallas, TX 75216. The period of performance is a base year from December 1, 2026 through November 30, 2027, with four additional one-year option periods extending through November 30, 2031. The contractor must deliver all necessary supplies and reagents at no government cost, ensure performance meets manufacturer specifications, and reimburse the government for referral lab costs if testing becomes unavailable due to contractor-related issues. The vendor will be evaluated on quality metrics such as repeat runs, peer comparison, invoice accuracy, backorder management, proactive notifications, recalls, and complaint resolution, with no access to VA data or systems.